GlassScriptPhysician profile
Christopher Roy Stelton
NPI 1013234624
$1,311.19
in general payments reported to CMS, 2019-2025
14 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2021: $69.82 · 2022: $136 · 2023: $348 · 2024: $175 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.63 | 2023-2025 | Lumigan, Alphagan P, Durysta |
| Regeneron Healthcare Solutions, INC. | $255.67 | 2019-2025 | Eylea Hd, Eylea |
| Harrow Eye, LLC | $214.87 | 2024-2025 | Iheezo |
| Genentech USA, INC. | $168.53 | 2021-2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $127.88 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $73.16 | 2025 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $36.95 | 2023 | |
| Apellis Pharmaceuticals, INC. | $30.75 | 2024 | Syfovre |
| Dompe US, INC. | $30.72 | 2025 | Oxervate |
| Ocular Therapeutix, INC. | $23.90 | 2023 | Dextenza |
| Alimera Sciences, INC. | $20.49 | 2023 | Iluvien |
| Bausch & Lomb Americas INC. | $19.30 | 2022 | |
| Allergan, INC. | $15.73 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.